Robert Bosch Healthcare Systems, Inc. v. Cardiocom, LLC

Filing 43

ORDER granting 19 Motion to Stay signed by Judge Edward J. Davila on 12/3/12. (ejdlc4, COURT STAFF) (Filed on 12/3/2012)

1
2
3
UNITED STATES DISTRICT COURT

4

NORTHERN DISTRICT OF CALIFORNIA

5

SAN JOSE DIVISION

6
7

ROBERT BOSCH HEALTHCARE
SYSTEMS, INC.,

8
9

United States District Court
For the Northern District of California

10

Plaintiff,
v.

Case No.: 5:12-CV-3864-EJD
ORDER GRANTING
DEFENDANT’S MOTION TO STAY
PENDING REEXAMINATION

CARDIOCOM, LLC,

11

Defendant.

12
13
14
15
16

Presently before the court is Defendant’s Motion to Stay Pending Reexamination of the six
patents-in-suit. For the reasons set forth below, the motion is GRANTED and the case is STAYED.
I.

BACKGROUND
The facts of this case are known to the parties and are only recited to the extent they are

17

applicable to the instant motion. On July 24, 2012 Plaintiff Robert Bosch Healthcare Systems, Inc.

18

(“Plaintiff”) filed this suit against Defendant Cardiocom, LLC for infringement of six of its U.S.

19

Patents: U.S. Patent Nos. 6,368,273 (“the ’273 patent”); 6,968,375 (“the ’375 patent”); 7,252,636

20

(“the ’636 patent”); 7,941,327 (“the ’327 patent”); 8,015,025 (“the ’025 patent); and 8,140,663

21

(“the ’663 patent”). Two of the patents in suit, the ’273 and the ’375 patents, were previously

22

raised with Defendant via a September 13, 2006 letter sent from Health Hero Network, Inc.

23

(“Health Hero”), Plaintiff’s predecessor-in-interest. Defendant responded on January 24, 2007,

24

denying infringement and declining to take a license from Plaintiff. No further communications

25

transpired between the parties until the filing of this action. The remaining four patents-in-suit

26

issued after this exchange; however, each of these patents share overlapping specifications and are

27

related to the ’273 and ’375 patents.

28
1
Case No.: 5:12-CV-3864-EJD
ORDER GRANTING DEFENDANT’S MOTION TO STAY PENDING REEXAMINATION

1

Less than two months after Plaintiff brought this action, Defendant filed petitions to

2

reexamine each of the patents-in-suit. Defendant filed an ex parte reexamination request of the

3

’273 patent, and inter partes reexamination requests of the ’025, ’663, ’327, ’636, and ’375 patents.

4

The last of these applications was filed on September 13, 2012. Defendant seeks a stay of this

5

action pending the final exhaustion of these six reexaminations.

6
7

II.

LEGAL STANDARDS
“Any person at any time may file a request for reexamination by the [PTO] of any claim of

8

a patent on the basis of any prior art” consisting of patents or printed publications. 35 U.S.C. § 302

9

(amended 2011). “Congress instituted the reexamination process to shift the burden or

United States District Court
For the Northern District of California

10

reexamination of patent validity from the courts to the PTO.” Canady v. Erbe Elektromedizin

11

GmBH and Erbe U.S.A., 271 F.Supp.2d 64, 78 (D.D.C. 2002). “The stay of pending litigation to

12

enable PTO review of contested patents was one of the specified purposes of the reexamination

13

legislation.” Patlex Corp. v. Mossinghoff, 758 F.2d 594, 606 (1985), aff'd on reh ‘g, 771 F.2d 480

14

(Fed. Cir. 1985).

15

A stay is within the discretion of the court. See Ethicon, Inc. v. Quigg, 849 F.2d 1422,

16

1426-27 (Fed. Cir. 1988) (“Courts have inherent power to manage their dockets and stay

17

proceedings, including the authority to order a stay pending conclusion of a PTO reexamination.”).

18

A court may grant a motion to stay “in order to avoid inconsistent results, narrow the issues, obtain

19

guidance from the PTO, or simply to avoid the needless waste of judicial resources, especially if

20

the evidence suggests that the patents-in-suit will not survive reexamination.” MercExchange,

21

L.L.C. v. eBay, Inc., 500 F.Supp.2d 556, 563 (E.D. Va. 2007). In this district, “there is a liberal

22

policy in favor of granting motions to stay proceedings pending the outcome of USPTO

23

reexamination or reissuance proceedings,” (ASCII Corp. v. STD Entm’t USA, 844 F.Supp. 1378,

24

1381 (N.D. Cal. 1994)), though some courts have begun to rethink that policy in recent years (see,

25

e.g., Network Appliance Inc. v. Sun Microsystems Inc., No. 07-CV-06053, 2008 WL 2168917 at

26

*3 (N.D. Cal. May 23, 2008)).

27
28

Courts consider three main factors in determining whether to stay a case pending
reexamination: “(1) whether discovery is complete and whether a trial date has been set; (2)
2
Case No.: 5:12-CV-3864-EJD
ORDER GRANTING DEFENDANT’S MOTION TO STAY PENDING REEXAMINATION

1

whether a stay will simplify the issues in question and trial of the case; and (3) whether a stay

2

would unduly prejudice or present a clear tactical disadvantage to the non-moving party.” Telemac

3

Corp. v. Teledigital, Inc., 450 F.Supp.2d 1107, 1111 (N.D. Cal. 2006) (citation omitted).

4
5

III.

DISCUSSION
a. STAGE OF PROCEEDINGS
The early stage of a litigation weighs in favor of a stay pending reexamination. See Target

7

Therapeutics, Inc. v. SciMed Life Sys. Inc., 33 U.S.P.Q.2d 2022, 2023 (N.D. Cal. 1995). Plaintiff

8

does not appear to genuinely dispute that this litigation is in a very early stage. Plaintiff filed this

9

case less than four months ago and Defendant answered less than three months ago. The parties

10
United States District Court
For the Northern District of California

6

have not engaged in any discovery nor exchanged initial disclosures. This court has not issued a

11

scheduling order, and has not set a claims construction hearing or a trial date. Accordingly, the

12

first factor weighs heavily in favor of a stay.

13
14

b. SIMPLIFICATION OF ISSUES
“[W]aiting for the outcome of the reexamination could eliminate the need for trial if the

15

claims are cancelled or, if the claims survive, facilitate trial by providing the court with expert

16

opinion of the PTO and clarifying the scope of the claims.” Target Therapeutics, 33 U.S.P.Q.2d at

17

2023. Here, each of the claims asserted by Plaintiff in this litigation is subject to reexamination.

18

The majority of these claims are subject to inter partes reexamination. Statistically these claims

19

have a greater chance of being canceled or amended than they do of being confirmed. See

20

Pragmatus AV, LLC v. Facebook, Inc., No. 11–CV–02168–EJD, 2011 WL 4802958 at *3, (N.D.

21

Cal. Oct.11, 2011) (“44% of all reexamination proceedings between 1999 and June 30, 2011

22

resulted in all claims being canceled, 43% changed the claims, and only 13% confirmed all

23

claims.”). The claims subject to the ex parte reexamination do not stand a much greater chance of

24

surviving completely unchanged. The PTO’s data shows that 22% of ex parte reexaminations

25

result in all claims being confirmed, 11% result in all claims being cancelled, and 67% result in

26

amended claims. U.S.P.T.O., “Ex Parte Reexamination Filing Data – June 30, 2012”, Dkt. No. 21,

27

Ex. H at 2. Given the likelihood that the scope of Plaintiff’s claims will be altered or even

28

cancelled, the court finds that the issues in this case stand to be clarified by a stay.
3
Case No.: 5:12-CV-3864-EJD
ORDER GRANTING DEFENDANT’S MOTION TO STAY PENDING REEXAMINATION

1

Plaintiff argues that because it is statistically unlikely that the reexaminations will finally

2

resolve all the issues in this litigation, a stay will not aid the court in simplifying the issues in this

3

case. The court disagrees. When a reexamination stands to simplify some, if not all, of the issues

4

in a case, the second factor may still properly weigh in favor of a stay. See, e.g. Convergence

5

Tech. (USA), LLC v. Microloops Corp., No. 10-CV-02051, 2012 WL 1232187 at *3-4 (N.D. Cal.

6

Apr. 12, 2012); but cf Athena Feminine Tech. Inc. v. Wilkes, No. 10-CV-04868, 2012 WL

7

1424988, at *3 (N.D. Cal. Apr. 24, 2012) (denying a stay because, inter alia, the outcome of the

8

reexamination process did not stand to resolve all of the legal claims in the case, including non-

9

patent related claims such as misappropriation of trade secrets, breach of contract, and unfair

United States District Court
For the Northern District of California

10

competition). Here, it seems more likely than not that at least some of the claims may be at least

11

amended during reexamination. In that case, the court would greatly benefit from the PTO’s

12

guidance as to the scope of the claims. Even if every claim survives reexamination unchanged, this

13

case will still be simplified because Defendant will be estopped from asserting any invalidity

14

arguments it could have raised in its five inter partes reexaminations. 35 U.S.C. § 315(c). The

15

court thus finds that this second factor weighs in favor of a stay.

16

c. UNDUE PREJUDICE OR CLEAR TACTICAL DISADVANTAGE

17

The third, and in this case the most critical, factor of the stay analysis focuses on the undue

18

prejudice or tactical disadvantage the non-moving party stands to suffer should a stay issue. See In

19

re Cygnus Telecomm. Tech., LLC Patent Litig., 385 F.Supp.2d 1022, 1023 (N.D. Cal. 2005).

20

Plaintiff argues that it will suffer an unfair disadvantage because it is a direct competitor with

21

Defendant in the telehealth market and particularly in a time-limited market created by the U.S.

22

Department of Veterans Affairs, because its patents will likely expire before reexamination and any

23

subsequent trial proceedings conclude, and because Defendant compounded Plaintiff’s

24

disadvantage by delaying its request for reexamination and selecting a longer reexamination

25

process. The court will address each of these arguments in turn.

26

Plaintiff first asserts that, by virtue of the parties’ positions as direct competitors, money

27

damages cannot sufficiently compensate for any harm caused by a stay. “Unlike patent

28

infringement actions involving non-practicing entities, infringement among competitors can cause
4
Case No.: 5:12-CV-3864-EJD
ORDER GRANTING DEFENDANT’S MOTION TO STAY PENDING REEXAMINATION

1

harm in the marketplace that is not compensable by readily calculable money damages.” Avago

2

Tech. Fiber IP (Singapore) Pte. Ltd. V. IPTronics, Inc., No. 10-CV-02863, 2011 WL 3267768, at

3

*5 (N.D. Cal. July 28, 2011) (citing Acumed LLC v. Stryker Corp., 551 F.3d 1323, 1327-28 (Fed.

4

Cir. 2008)). As competitors in a relatively new market, Plaintiff argues, the parties are “struggling

5

to establish themselves in the market place and to secure their section of the market.” Pl. Opp. at

6

*6, Dkt. No. 23. Once market share is established it is unlikely to significantly shift soon

7

thereafter because customers, mainly healthcare providers, will be reluctant to undertake the time

8

and expense required to convert systems. Time is thus of the essence to establish contracts and

9

relationships. Plaintiff specifically points to the fact that both itself and Defendant are currently

United States District Court
For the Northern District of California

10

competing for $225 million worth of contracts over the next five years with the Department of

11

Veterans Affairs. Because Defendant’s product uses Plaintiff’s technology as covered by the

12

patents-in-suit, Plaintiff argues, money damages will not adequately compensate for Defendant’s

13

unfair competition in this nascent, and in the case of the Department of Veterans Affairs, time-

14

limited, market.

15

While it is true that competition based on alleged infringement can weigh against a stay, it

16

is not a compelling argument in this case. Here, Plaintiff licenses the patents-in-suit to several

17

other competitors, and has offered a license to Defendant. Through its licensing efforts, Plaintiff

18

has enabled other companies to directly compete in its own market, thus creating competition for

19

relationships, opportunities, and market share. Given that Plaintiff has not used the patents-in-suit

20

to keep competitors out of the market, it cannot now argue that it will suffer an unfair disadvantage

21

by Defendant’s ongoing competition during any stay period. Should infringement ultimately be

22

found in this case, money damages will adequately compensate Plaintiff for any lost licensing

23

revenues.

24

Next, Plaintiff argues that it will be unfairly disadvantaged by a stay because the patents-in-

25

suit will likely expire before the reexamination proceedings and any subsequent trial has reached

26

completion. As this court has previously stated, the delay inherent to the reexamination process

27

does not generally, by itself, constitute undue prejudice. Telemac Corp. v. Teledigital, Inc., 450

28

F.Supp.2d 1107, 1111 (N.D. Cal. 2006). As evidenced by Health Hero’s September 13, 2006
5
Case No.: 5:12-CV-3864-EJD
ORDER GRANTING DEFENDANT’S MOTION TO STAY PENDING REEXAMINATION

1

letter, Plaintiff and its predecessor were aware of Defendant’s possible infringement for at least six

2

years before filing suit. Plaintiff’s own strategic decision to bring this action now, less than three

3

years before its patents-in-suit begin to expire, does not create the undue prejudice necessary to

4

shield it from the potential negative consequences of Defendant’s strategic response.

5

Finally, Plaintiff argues that Defendant’s initial delay in seeking reexamination, followed
by its rush to file reexamination requests before the new and quicker America Invents Act

7

reexamination procedures became effective on September 16, 2012, compounded Plaintiff’s

8

tactical disadvantage. Pointing to the 2006 Health Hero letter and its various other lawsuits against

9

competitors, Plaintiff suggests that its own pre-litigation conduct put Defendant on notice of the

10
United States District Court
For the Northern District of California

6

patents-in-suit, and created a duty for Defendant to seek reexamination. This argument is both

11

unfounded and unconvincing. Defendant cannot be faulted for failing to seek reexamination before

12

it was served with Plaintiff’s summons and complaint. Defendant declined to take a license from

13

Health Hero via a January 2007 letter and thereafter heard nothing of the matter until Plaintiff filed

14

this action in July 2012. This brief exchange six years ago created no duty for Defendant to

15

undertake the time and expense of requesting reexamination. Additionally, even if Defendant was

16

aware of Plaintiff’s active infringement litigation against other parties, such notice created no duty

17

for Defendant, a third party, to seek reexamination. Once sued, Defendant acted promptly by filing

18

six reexamination requests within two months. In filing its lawsuit less than two months before the

19

implementation of a major overhaul to the inter partes reexamination proceedings, Plaintiff

20

certainly should have been aware that Defendant would face the choice of submitting any

21

reexamination requests under the old or the new regimes. Plaintiff cannot be prejudiced by a

22

litigation decision it itself afforded its opponent. Therefore, that Defendant submitted its requests

23

just days before new reexamination procedures were to be instituted did not constitute an undue

24

prejudice towards Plaintiff.

25

Plaintiff’s arguments that it will be tactically disadvantaged by a stay, while numerous, are

26

not compelling. In each instance, Plaintiff has essentially constructed the environment that created

27

any disadvantage it stands to suffer. Therefore, the court finds that the undue prejudice factor

28

weighs in favor of a stay.
6
Case No.: 5:12-CV-3864-EJD
ORDER GRANTING DEFENDANT’S MOTION TO STAY PENDING REEXAMINATION